ClinicalTrials.gov
public full text
Public Domain
The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC
Camrelizumab is an antibody targeting programmed death receptor 1 (PD-1) and its ligand programmed death-ligand 1 (PD- L1) that is designed to boost the immune system. It does this by allowing immune cells to fight the cancer. Stereotactic body radiotherapy is a potential immunostimulatory therapy that may amplify antitumor response when combined with camrelizumab.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)#1031138
- HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC#912416
- Radiotherapy With Neoadjuvant Chemotherapy and Immunotherapy in Rectal Cancer#887707
- A Phase Ib/II Study of Adebrelimab in Combination with Capecitabine and Oxaliplatin in Cancer#1093082
- Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer#876874
Record · ID 1058020
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive